---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-060254"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2023-07-27T23:59:59+00:00"
generated_at: "2026-06-13T00:56:51.790428+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Allarity adds Benjamin, Oliver, Vazzano as directors; cures Nasdaq compliance gap

## Summary
- Director David Roth resigned July 21, 2023 for personal reasons; Board expanded from 5 to 7 seats.
- Appointed Laura Benjamin (OncXerna CEO), Robert Oliver (ex-Otsuka America CEO), Joseph Vazzano (Abeona CFO) as independent directors effective Aug 1, 2023.
- New board: 4 of 6 independent; Audit & Comp committees fully independent; expected to cure Nasdaq independence rules.
- Independent directors receive $50k annual retainer plus committee fees; each gets options for 2,300 shares subject to stockholder approval.

## SEC filing metadata
- accession: 0001213900-23-060254
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2023-07-27T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 3.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390023060254/0001213900-23-060254-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390023060254/ea182404-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-060254
- JSON: https://secwatch.observer/filing/0001213900-23-060254.json
- Plain text: https://secwatch.observer/filing/0001213900-23-060254.txt

## Key facts
- Executive change
  Joe Vazzano was appointed as Director at Allarity Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: Class I Director: Mr. Joe Vazzano, whose term will expire at the Company’s 2026 annual meeting of stockholders or until his respective successors are duly elected and qualified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390023060254/0001213900-23-060254-index.htm
- Executive change
  David Roth resigned as Director at Allarity Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On July 21, 2023, the Board of the Company received the resignation of Dr. David Roth as director of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390023060254/0001213900-23-060254-index.htm
- Executive change
  Robert Oliver was appointed as Director at Allarity Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: Class III Director: Mr. Robert Oliver, whose term will expire at the Company’s 2025 annual meeting of stockholders or until his respective successors are duly elected and qualified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390023060254/0001213900-23-060254-index.htm
- Executive change
  Laura Benjamin was appointed as Director at Allarity Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: Class II Director: Dr. Laura Benjamin, whose term will expire at the Company’s 2024 annual meeting of stockholders or until her respective successors are duly elected and qualified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390023060254/0001213900-23-060254-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.